Expression of Thy-1 on Human Hematopoietic Progenitor Cells
Overview
General Medicine
Authors
Affiliations
Expression of Thy-1 on hematopoietic cells from human fetal liver (FL), cord blood (CB), and bone marrow (BM) was studied with a novel anti-Thy-1 antibody, 5E10. Specificity of 5E10 for human Thy-1 was demonstrated by immunoprecipitation of a 25-35-kD molecule, and the sequence of a cDNA that was cloned by immunoselection of COS cells transfected with a cDNA library derived from a 5E10+ cell line. Two- and three-color immunofluorescence staining experiments revealed that the Thy-1 expression is restricted to, an average, 1-4% of FL, CB, and BM cells, and binding to these cell types is essentially restricted to a very small subset of lymphoid cells and approximately 25% of CD34+ cells. Thy-1+ CD34+ cells were further characterized as CD38lo/CD45RO+/CD45RA-/CD71lo/c-kit(lo) and rhodamine 123dull. When CD34+ cells were sorted on the basis of Thy-1 expression, the majority of clonogenic cells were recovered in the CD34+Thy-1- fraction, whereas the majority of cells capable of producing myeloid colonies after 5-8 wk of long-term culture (long-term culture initiating cells) were recovered in the Thy-1+CD34+ fraction. In addition to CD34+ cells, Thy-1 was found to be expressed on a variable, very small number (< 1%) of CD34- mononuclear cells in BM, CB, and peripheral blood that were further characterized as CD3+ CD4+ lymphocytes. The restricted expression of Thy-1 on primitive hematopoietic cells is in agreement with a previous report (Baum et al., 1992. Proc. Natl. Acad. Sci. USA. 89:2804) in which Thy-1 expression was used to enrich for primitive hematopoietic cells from fetal tissue. Compared with those previous studies, we found Thy-1 expression on a larger proportion of CD34+ cells (25% in our study vs. 5% in Baum et al.) and furthermore performed studies on Thy-1 expression on CD34+ cells from CB, FL, and BM in relation to markers that are known to be differentially expressed on hematopoietic cells. Taken together our results indicate that Thy-1-specific antibody 5E10 is an attractive tool for further studies on the biology and purification of human stem cells.
Allouh M, Rizvi S, Alamri A, Jimoh Y, Aouda S, Ouda Z Stem Cell Res Ther. 2025; 16(1):127.
PMID: 40055783 PMC: 11889844. DOI: 10.1186/s13287-025-04254-0.
Rohan P, Dos Santos E, Abdelhay E, Binato R Genes (Basel). 2024; 15(1).
PMID: 38254918 PMC: 10815053. DOI: 10.3390/genes15010028.
CD90-targeted lentiviral vectors for HSC gene therapy.
Berckmueller K, Thomas J, Taha E, Choo S, Madhu R, Kanestrom G Mol Ther. 2023; 31(10):2901-2913.
PMID: 37550965 PMC: 10556220. DOI: 10.1016/j.ymthe.2023.08.003.
Dynamics of human hematopoietic stem and progenitor cell differentiation to the erythroid lineage.
Schippel N, Sharma S Exp Hematol. 2023; 123:1-17.
PMID: 37172755 PMC: 10330572. DOI: 10.1016/j.exphem.2023.05.001.
What is new in cancer-associated fibroblast biomarkers?.
Zhao Z, Li T, Yuan Y, Zhu Y Cell Commun Signal. 2023; 21(1):96.
PMID: 37143134 PMC: 10158035. DOI: 10.1186/s12964-023-01125-0.